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Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of
the gastrointestinal tract. The discovery that these tumors, formerly thought of smooth
muscle origin, are indeed better characterized by specific activating mutation in genes cod-
ing for the receptor tyrosine kinases (RTKs) CKIT and PDGFRA and that these mutations
are strongly predictive for the response to targeted therapy with RTK inhibitors has made
GISTs the typical example of the integration of basic molecular knowledge in the daily clini-
cal activity.The information on the mutational status of these tumors is essential to predict
(and subsequently to plan) the therapy. As resistant cases are frequently wild type, other
possible oncogenic events, defining other “entities,” have been discovered (e.g., succinil
dehydrogenase mutation/dysregulation, insuline growth factor expression, and mutations
in the RAS-RAF-MAPK pathway). The classification of disease must nowadays rely on the
integration of the clinico-morphological characteristics with the molecular data.
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are the most frequent
mesenchymal tumors of the gastrointestinal tract, with an inci-
dence between 15 and 20 new cases/10,00,000/year (1, 2). The
actual incidence may be, however, higher, as incidental GISTs
are relatively frequent (3–6). The most frequent localization is
the stomach, followed by the small intestine, the colon–rectum,
and the esophagus (7). The existence of true extragastrointestinal
GISTs is controversial. Although the concept that mesenchymal
tumors of the gastrointestinal tract with leiomyomatous morphol-
ogy are “bizarre” or “blastomatous” had been established almost
70 years ago by Stout (8, 9), the actual histogenesis of these tumors
was defined about 30 years ago (in the pre-immunohistochemistry
era) by Mazur and Clark (10), who proposed the non-committal
term of “Gastrointestinal stromal tumors.” With the development
of immunohistochemistry, the concept could be better specified.
Most cases (70%) were positive for CD34, and the expression
of smooth muscle markers was seen in less than 50%. CD34 is
normally expressed in endothelia, in hematopoietic stem cells,
perivascular fibroblasts, and stromal fibroblasts in various local-
ization, thus underlining the “stromal,” but uncommittal nature
of these tumors (11). Moreover, CD34 is expressed in a propor-
tion of interstitial cells of Cajal (ICC), the pacemaker cells of the
gastrointestinal tract (12). In 1998, two groups (13, 14) showed
independently that more than 80% of these enigmatic tumors har-
bor constitutively activating mutations of the ckit gene that encode
an important receptor tyrosine kinase (RTK) type III. CKIT (also
known as CD117) immunohistochemical expression was contem-
porarily reported in more than 95% of GIST cases, thus becoming
an important tool for the diagnosis (15, 16) (Figure 1). The
immunophenotype is shared by the ICC (17), so that Kindblom
et al. proposed in their paper the term “GIPACT,” GastroIntesti-
nal PAcemaker Cells Tumor. This term was, however, not retained.
Although sometimes questioned, the theory of origin from ICC
is nowadays generally accepted. In 2003, it was shown that a
substantial fraction of CKIT-wild-type GISTs’ harbor-activating
mutations in pdfgra (platelet-derived growth factor alpha) gene,
coding for another important RTK type III (18). This confirms
that the oncogenesis of GISTs is probably related to early activa-
tion of RTKs. Interestingly, the immunohistochemical positivity
for CD117 is independent from the mutational status of RTK genes
(19). Another almost pathognomonic IHC marker is DOG-1, cor-
responding to the potassium transporter ANO1 (Figure 1D). The
importance of the RTK mutational status is also underlined by
the fact that CKIT and PDGFRA are very good target for the tar-
geted therapy with the RTK inhibitor imatinib mesylate (Gleevec®,
Novartis Pharma AG, Basel, Switzerland). Imatinib is now the first-
line option in the medical treatment of GISTs (1, 20). Imatinib is
approved in US and in Europe for adjuvant therapy (21) and may
be used also in a neoadjuvant setting to reduce the tumor mass
(1). Imatinib is very effective on sensitive GISTs as it was shown in
the communication of Joensuu published in “The New England
Journal of Medicine” in 2003 (22).
The therapy with imatinib has become the paradigm of targeted
therapy in solid tumors. In spite of this great success, primary and
secondary resistance to targeted therapy remains a problem to
solve. Beneath a minority of GISTs that simply do not respond to
the therapy with imatinib (primary resistance), due probably to
their genetic constitution (see below), half of the patients develop
disease progression after 2 years of treatment with imatinib (23).
The main predictor of the response to therapy is represented by
the mutation in the RTK genes (7, 21, 24). The genetic alterations
in the RTK genes are important early events in the oncogenesis of
GISTs, and define the response to targeted therapy.
Recently, mutations in BRAF and KRAS, both belonging to the
RAS-RAF-MAPK pathway (25, 26), and hyperexpression of the
transcription factor ETV1 (27) have been described.
The understanding of GISTs biology has stimulated the devel-
opment of RTK inhibitors. Nowadays, there are at least three
molecules that can be used against KIT and/or PDGFRA. The
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FIGURE 1 | Histology, immunohistochemistry, and molecular genetics
of GISTs. (A,B) Histology. (A) Spindle cell tumor, with paranuclear
vacuoles (so-called “leiomyoblastoma”). HE 40×. (B) Epitheloid tumor.
Large, clear cytoplasm with central nucleus. HE 40×. (C) Spindle cells
diffusely positive for CKIT (CD117). IHC 10×. (D) Epitheloid cells strongly
and diffusely positive for DOG1, with evident membrane enhancement.
IHC 40×. (E) Sanger sequencing with a duplication of GCC TAT in positions
502–503 (p.A502-Y503 dup). Mutation associated with sensitivity to
imatinib. (F). Sanger sequencing with a substitution (A–C) in position 842,
(p.D842V), imatinib resistant.
evolution of the idea of GISTs represents also how our par-
adigm of classification of disease is changing. From a “mor-
phologic/etiologic” classification, we are going to more dynamic
and flexible criteria, where the “old” clinicopathologic parame-
ters are integrated with/substituted by the molecular alterations.
This process is advancing also in other fields of oncology, as
shown e.g., by the fourth edition of the WHO/IARC “blue books”
(http://www.iarc.fr/en/research-groups/sec4/).
This review will, therefore, focus on the biology and molecular
pathology of GISTs, and on the evolution of their classification.
MOLECULAR ALTERATIONS IN GISTs
RTK III
CKIT and PDGFRA are RTK III, together with PDGFRB,
macrophage colony-stimulating-factor receptor (CSFR1), FLT1,
Flk/KDR, and Fl cytokine receptor (FLT3) (28, 29). RTK III have
five Ig-like extracellular domains, one transmembrane domain,
one intracellular juxtamembrane regulatory domain, and two
intracellular tyrosine kinase domain with autophosphorylating
capacity (29) (Figure 2). CKIT and PDGFRA are located on the
same chromosomal region (4q12) and are very similar, both in
the sequence and in the structure (29). The ligands (stem cell fac-
tor, SCF for CKIT and platelet-derived growth factor, PDGF for
PDGFRA) cause homodymerization of the receptor. Subsequently,
the TK domains autophosphorylate and activate, triggering the
metabolic pathways of RAS-RAF-MAPK, PI3K-AKT, and signal
transducer and activator of transcription 3 (STAT3) (30–34).
CKIT
CKIT is crucial in the development of different cell types, in par-
ticular melanocytes, hematopoietic progenitor cells, mast cells,
primordial germ cells, and, last but not least ICC, the proba-
ble cells of origin of GISTs (17, 21, 35). KIT-activating muta-
tions are important for the genesis and development of sev-
eral human tumor types: seminoma/dysgerminoma, mastocytosis,
acute myeloid leukemia, melanoma, and GIST (36–39). CKIT can
be, therefore, considered as an important oncogenetic factor in
various different tissues.
Germline KIT mutations are very rare and they are associated
with familial GISTs (21), while activating mutations are generally
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CKIT 
Ig-like EC domain 
Exon 9 (10%) 
Exon 11 (70%) 
Exon 13 (1%) 
JM (regulatory) Exon 12 (<1%) 
TK1 Exon 14 (<1%) 
Exon 17 (1%) TK2 (ac!va!on loop) Exon 18 (5-7%) 
PDGFRA 
FIGURE 2 | Structure of RTK III, with localization of the activating
mutations in KIT and PDGFRA. EC, extracellular; JM, juxtamembrane; TK,
tyrosine kinase.
somatic and cause homodymerization of KIT and subsequent
tyrosine kinase activation without SCF binding. Activating muta-
tions are most frequently (60–70% of cases) found in exon 11 of
CKIT gene (7), corresponding to the juxtamembrane intracellu-
lar regulatory domain of the protein (Figure 2). Because of exon
11 mutations, the protein changes its structure from the inactive
into the active state (40). There are many different mutation types
(in-frame deletions, insertions, substitutions) in various combi-
nations (24, 29, 41). The kind of the alteration is clearly associated
with clinicopathologic characteristics, such as prognosis and local-
ization. For instance, deletions, of codons 557–558, are associated
with shorter overall and disease-free survival (42–45), whereas
tandem internal duplications (Figure 1E) are associated with a
relatively indolent course (46, 47).
Exon 9 (corresponding to the extracellular domain of the KIT
molecule) mutations are present in almost 10% of GIST cases
(7, 48) and are almost only duplications of six nucleotides, cor-
responding to the A502_Y503 residues of the protein (49). The
mutations probably induce conformational changes similar to
SCF binding, leading to autoactivation. Exon 9-mutated GISTs
are more often localized in small intestine or colon and have
poorer prognosis (47–53). They have also different gene expression
signatures (50).
Mutations in tyrosine kinase domain (exon 17) and ATP-
binding site (exon 13) are rare and generally not primary (7, 34,
42, 51–60). They are generally secondary mutations arising dur-
ing the targeted treatment with receptor tyrosine kinase inhibitors
(RTKI), and induce secondary resistance (58–60) (see below).
Most KIT exon 13 mutations are single substitutions leading to
K642E in the aminoacidic sequence (52).
Recently, deletion of codon 419 in exon 8 of KIT (correspond-
ing to the extracellular domain) have been described in a very
small subset of GIST (≈0.2% of all cases) (61). This mutation was
found also in systemic mastocytosis. Interestingly, it seems that
this mutation is associated with sensitivity to RTKI.
Activating mutations of KIT trigger pathways, such as MAPK,
PI3K-AKT, and STAT3 (30, 33, 62–66). The MAPK pathway is
functionally related to several transcription factors (e.g., MYC,
ELK, and CREB) and finally positively controls the cell cycle
(67). The PI3K pathway, through phosphorylation of AKT and
PDK1, acts against the apoptosis and indirectly stimulates the cell
cycle (68). Phosphorylation of STAT3 triggers its transport in the
nucleus and behaviors as a transcription factor, with a positive
effect on proliferation and a negative effect on apoptosis (69).
Activation of RTK is surely pivotal in the oncogenetic pathway
of GISTs, and represents an early event, but is not the exclusive fac-
tor for the acquisition of the transformed phenotype. For instance,
a very interesting and elegant study has been published (27), sug-
gesting that ETV1 (ETS translocation variant 1) may interact with
KIT in the oncogenesis. The clinical importance of ETV1, however,
is controversial (70, 71).
Proteasome degradation regulates physiological levels of KIT.
Mutated KIT is degraded more slowly than wild-type KIT, proba-
bly because of physical interaction with heat-shock protein 90 (72,
73). HSP90 inhibitors are indeed effective in experimental models
of GISTs (74).
PDGFRA
PDGFRA has similar sequence and function as KIT. It is mutated
in GISTs and AML and translocated on FILP1 in hematologic
malignancies (21). Activating mutations in KIT and PDGFRA are
mutually exclusive in GISTs (18, 31). Mutations in PDGFRA are
in exons 12, 14, and 18, corresponding to the juxtamembrane
regulatory domain and the tyrosine kinase domain of the pro-
tein, respectively (exons 11, 13, and 17 of KIT). PDGFRA-mutated
GISTs are 10–12% of all cases (53, 56, 57, 75–79). They have epith-
eloid morphology and are generally gastric tumors, showing an
indolent course (80–82). They also have different gene expression
signatures (32, 83). On the other hand, the immunohistochem-
ical phenotype (positivity for CD117, DOG-1, and PKC-Theta),
the chromosomal alteration (deletion of 14q and 22q), and the
biochemical properties (activated pathways and stabilization by
HSP90) of PDGFRA-mutated GISTs overlap with CKIT-mutated
tumors (84–87). The most frequent mutations in PDGFRA involve
the aspartic acid in position 842 (Figure 1F) and are generally not
sensitive to imatinib (18, 79, 88–95). Insertions and duplications
are very rare, while deletions and deletions/insertions between
codon 840 and 849 are more frequent. In exon 12, the most fre-
quent mutation is a substitution T -> A, leading to a Val561Asp
(19). In-frame deletions are also relatively frequent in exon 12,
clustering in codons 559–72. Mutations in exon 14 are exceptional.
RAS-RAF-MAPK PATHWAY
In all, 10–15% of GISTs are wild type both for KIT and PDGFRA.
This genotype is not related to the immunophenotype, namely
with the positivity to KIT (CD117) and DOG1 stainings. Sev-
eral “wt”-GISTs are strongly positive for CKIT (CD117), and the
involvement of RTK has been proved functionally (phosphoryla-
tion and subsequent activation) (30). These so-called “wild-type”
GISTs are a very heterogeneous group, showing different, probably
oncogenic mutations. BRAF V600E has been described in 13% of
“wild-type” GISTs (25, 58, 96). At the beginning, it was thought
that the BRAF mutations were characteristic of “wild-type” GISTs.
In a recent study, Miranda et al. (26) have suggested that BRAF
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is mutated in ca., 2% of GISTs carrying KIT or PDGFRA muta-
tion, thus suggesting a further mechanism of primary resistance
to imatinib treatment (see below). In the same study, 5% of GISTs
carrying mutations in KIT or PDGFRA showed mutation in codon
2 of KRAS (G12A or G13D). Also, mutations in HRAS and NRAS
have been found, but they are very rare. The presence and, above
all, the meaning of mutations in KRAS were questioned by a recent
study on 450 GISTs sequenced with Sanger’s method (97).
NEUROFIBROMATOSIS 1
Neurofibromatosis 1 (NF1) (von Recklinghausen disease) is an
autosomal dominant inherited disease, characterized by multiple
neurofibromas,café-au-lait spots, and other mesenchymal tumors.
NF1 is caused by inactivating mutations in the gene NF1, local-
ized on chromosome 17, coding for neurofibromin (98). Patients
with NF1 have an increased risk to develop multiple GISTs, with
a spindle cell morphology and with predominant intestinal loca-
tion (99). The tumors have rarely,“uncommon”mutations in RTK,
but CKIT and PDGFRA most often are not mutated (100–104).
Neurofibromin is analog to guanosine triphosphatase (GTPase)
activating proteins (GAPs), which control the level and activity
of RAS. Loss of NF1 leads to high levels of active RAS. Hyper-
activation of the MAPK pathway is a consequence of somatic
inactivation of wild-type NF1 allele in GISTs (105). From the
cytogenetic point of view, they share deletion of 14q and 22q with
classical GISTs.
SUCCINATE DEHYDROGENASE COMPLEX
Succinate dehydrogenase complex (SDH) is a heterotetramer com-
posed by four subunits (SDHA-D), localized in the inner mito-
chondrial membrane. Subunit A oxidizes succinate to fumarate
in the Krebs’ cycle. Subunit B participates in the electron trans-
port chain for the oxidation of ubiquinone to ubiquinol, and
subunits C and D (SDHC and SDHD) are membrane-anchoring
subunits (106). SDH deficiency characterizes subsets of different
tumors (e.g., GISTs, paragangliomas, renal cell carcinomas, and
pituitary adenomas) (107, 108). SDH-deficient GISTs (identified
by immunohistochemical negativity for SDHB) are the largest
subgroup of “wt-GIST” (109, 110). They are always found in
the stomach, are epitheloid, and often multiple and resistant to
imatinib. Moreover, in contrast to “classical” GISTs, they metas-
tasize to lymph nodes, and show activation of insuline growth
factor receptor (IGFR). Their prognosis is not determined only
by size, site, and mitotic index (110–116). They have an indolent
course and even with liver metastases, the patients live long. SDH-
deficient GISTs are the majority of pediatric GISTs in the stomach
(110) and are part of two syndromes: the Carney triad (asso-
ciation of paranganglioma, pulmonary chondroma, and gastric
GIST) and the Carney-Stratakis syndrome (association of GISTs
and paragangliomas) (113, 117). The genetic events involved in
the tumorigenesis of these tumors are not yet completely clar-
ified (118, 119) and, in half of them, no mutation has been
identified, although the IHC staining for SDH is negative (120).
Defects of SDHx (independent from the involved subunit) induce
accumulation of succinate, which inhibits degradation of HIF, sub-
sequent increase of HIF levels, and its translocation in the nucleus,
where HIF triggers the transcription of VEGF and IGF1R (121,
122), with aberrant proliferation and tumorigenic responses. A
review of more than 1000 GISTs has shown that IGF1R expres-
sion is preferentially expressed in gastric SDH-deficient GISTs, but
never in intestinal GISTs (123). The role of the axis IGF-IGF1R
in maintaining the proliferative activity in GISTs has also been
confirmed, both experimentally and on a series of SDH-deficient
GISTs (124, 125).
CHROMOSOMAL ALTERATIONS
Chromosomal losses are much more frequent than chromosomal
gains in GISTs. Losses of 14q, 22q, and 1p are the most frequent
losses (126–128) and may subclassify GISTs in subsets with spe-
cific characteristics (129). Other losses are −9p, −11p, −17p,
−10q, −13q, and −15q. Combining array CGH and transcrip-
tome analysis Ylpaa et al. (130) have shown that the accumulation
of cytogenetic changes (chromosomal losses) parallels the evolu-
tion of the tumor and could be seen as “genetic staging.” Specific
genes (e.g., OXA1L on 14q and AKAP13 on 15q) are differentially
expressed in the different “genetic stages.”
Cytogenetic gains are relatively rare and localized, but are asso-
ciated with malignancy. In particular, gains on the loci for CCND1
and MDM2 gains have been shown to be associated with malig-
nancy (131). On the other hand, genes involved in cell cycle control
are dysregulated in high-risk tumors. Deletion or epigenetic inac-
tivation of the gene CDKN2A, encoding for p16 and p14, two
regulators of the cell cycle, is associated with malignant behavior
(132–134). p16 downregulation may cause through Rb phospho-
rylation E2F1-dependent transcription of genes essential for late
G1/S phase transition (135).
TARGETED THERAPY
The prognosis of high-risk/advanced GISTs has been very poor
until 2000. Surgery was the exclusive therapy, and the median
survival was less than 18 months (136). The introduction of ima-
tinib mesylate in the therapy changed dramatically this situation.
Imatinib was originally developed for chronic myeloid leukemia
(CML) (29). It has a very strong inhibitory activity against KIT,
fixing it in its inactive conformation. After the first communica-
tion of the dramatic success of the therapy in a case of advanced
metastatic GIST in a 50-year-old woman (22), it was rapidly intro-
duced in the therapy of metastatic non-resectable tumors and
is now approved also in the adjuvant setting, with a clear-cut
improving of the median survival (5 years). The most important
predictive factor of the response to targeted therapy is the muta-
tional status of the RTK genes (19, 21, 97). The best response
rate is achieved with mutations in exon 11 of CKIT gene that are
generally associated with a high response rate (≈80%), whereas
mutations in exon 9 are associated with a response rate of ≈45%
(91, 137) and deserve a higher doses of RTKI (Table 1). Muta-
tions in exon 13 and exon 17 of CKIT are generally not respon-
sive, such as mutations in codon 842 of PDFGRA and wt-GISTs
(see below).
In the attempt to achieve a better response to therapy, many
other different RTKI are in use or on trial. The best results have
been achieved with sunitib and regorafenib that are at present
used as second- and third-line treatments (138). A summary of
the possible targets and targeted drugs is shown in Figure 3.
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Table 1 | Integration between clinicopathologic and molecular criteria in the classification of GISTs.
Genetic alteration Mutation Frequency Localization Histology Prognosis Imatinib resp. Syndromes Remarks
KIT-MUTATED (≈70%)
Exon 9 (EC) Insertion AY502–503 ≈10% Small bowel
and colon
Spindle cell Poorer Partially resistant
(≈45% RR)
None Higher dose requested;
sunitinib
Exon 11 (JM) W557-K558del ≈70% Whole GI tract Spindle cell or
epithelioid cell
Poorer in stomach Generally
responsive
(≈80% RR)
Many different
familial GIST
syndromes
Deletion
Deletion–Insertions
Substitutions Better in stomach
Duplications Generally
stomach
Spindle cell Better in stomach
Exon 13 (TK) K642E 1% Whole GI Tract Poorer in stomach Responsive
V654A Poorer Resistant Causes secondary
resistance
T670I Poorer Resistant “Gatekeeper.”
Secondary resistance
Exon 17
(activation loop)
Substitutions (D816, D820,
N822)
0.5–1% Whole GI tract No prognostic
value
Resistant Secondary resistance
PDGFRA-MUTATED (≈7%)
Exon 12 (JM) Deletions/substitutions (e.g.,
V561D)
≈1% Stomach Epithelioid or
mixed spindle
cell/epithelioid
Indolent course Responsive Familial GIST
syndromes
Exon 14 (TK
domain)
N659K, N659I <1% Responsive None
Exon 18
(activation loop)
D842V, D842Y ≈5% Resistant Familial GISTs
Other substitutions <1% Responsive None
Deletions: I843, I843-H845,
D842-H845, D842-M844
1% All GI tract Responsive Familial GISTs
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w
w
w
.fro
n
tiersin
.o
rg
N
ovem
ber
2014
|Volum
e
1
|A
rticle
43
|5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
Ta
b
le
1
|C
o
n
ti
n
u
ed
G
en
et
ic
al
te
ra
ti
o
n
M
u
ta
ti
o
n
Fr
eq
u
en
cy
Lo
ca
liz
at
io
n
H
is
to
lo
gy
P
ro
g
n
o
si
s
Im
at
in
ib
re
sp
.
S
yn
d
ro
m
es
R
em
ar
ks
K
IT
W
T
/P
D
G
FR
A
W
T
(≈
15
%
)
S
D
H
x
m
ut
at
io
n
≈2
%
S
to
m
ac
h
E
pi
th
el
io
id
,
m
ul
tif
oc
al
In
do
le
nt
co
ur
se
.
N
B
:p
ro
gn
os
is
no
t
de
pe
nd
en
t
fr
om
si
ze
/m
ito
tic
in
de
x
R
es
is
ta
nt
C
ar
ne
y-
S
tr
at
ak
is
sy
nd
ro
m
e
(h
er
ed
ita
ry
),
C
ar
ne
y
Tr
ia
d
(n
on
-h
er
ed
ita
ry
)
IH
C
al
w
ay
s
ne
ga
tiv
e
fo
r
S
D
H
B
,m
ai
nl
y
fe
m
al
e,
hy
pe
re
xp
re
ss
io
n
of
IG
F1
R
B
R
A
F
V
60
0E
≈1
0%
Pr
ev
al
en
tly
sm
al
lb
ow
el
S
pi
nd
le
ce
ll
In
do
le
nt
co
ur
se
R
es
is
ta
nt
N
on
e
Po
ss
ib
le
m
ec
ha
ni
sm
of
re
si
st
an
ce
;o
bs
er
ve
d
in
R
TK
-m
ut
at
ed
G
IS
Ts
K
R
A
S
G
12
C
,G
13
D
<
1%
?
?
?
R
es
is
ta
nt
(?
)
?
R
ep
or
te
d
in
5%
of
R
TK
-m
ut
at
ed
G
IS
Ts
N
F1
<
1%
S
m
al
lb
ow
el
S
pi
nd
le
ce
ll
G
oo
d
pr
og
no
si
s
R
es
is
ta
nt
N
eu
ro
fib
ro
m
at
os
is
??
?
≈8
5%
A
ll
G
It
ra
ct
S
pi
nd
le
ce
ll
or
ep
ith
el
io
id
In
do
le
nt
co
ur
se
R
es
is
ta
nt
(p
ro
-
gr
es
si
ve
/s
ta
bl
e
di
se
as
e
in
69
%
)
??
Pa
th
w
ay
s
do
w
ns
tr
ea
m
?
O
th
er
s? RESISTANCE TO THERAPY
In spite of the dramatic success of the targeted therapy with RTKI,
there is evidence that also long-life imatinib treatment does not
destroy completely GIST cells (139, 140) and that resistance to
TKI therapy, both primary and secondary, arises in most of the
cases (141).
PRIMARY RESISTANCE
Progression within the first 6 months of treatment with imatinib
means primary resistance. The only predictor of primary resis-
tance is the mutation in RTK (CKIT and PDGFRA) genes (29,
141). The probability of primary resistance is 5% for mutations in
exon 11 of KIT, 16% for mutations in exon 9 of KIT, and 23% for
wild-type GIST (59, 142). Tumors with mutation in exon 9 need
a higher daily dose (800 mg instead of 400 mg) (29). Other CKIT
mutations (EC domain, TK domain, or activation loop, exons 8,
13, and 17) of KIT are rare and mostly associated with resistance,
although in some cases a response has been reported (e.g., K642E)
(61, 143). PDGFRA D842V mutation in the exon 18 is strongly
resistant to imatinib therapy, while other mutations in PDGFRA
are usually sensitive (91, 141, 144). The mechanisms of primary
resistance in “wild-type” KIT are probably multiple and not yet
clarified. One possibility is represented by alterations in molecules
“downstream” RTK, such as BRAF and KRAS, as hypothesized by
Miranda et al. (26). In NF1-related GISTs, that are resistant to
imatinib therapy, the activation of the MAPK-ERK axis due to
silencing of the NF1 gene (see above) is probably the chief fac-
tor for imatinib resistance (105). For pediatric or SDH-mutated
GISTs, that are almost invariably wild type for RTK, other possible
targets may be KDR (VEGFR) or mTOR (41, 109).
SECONDARY RESISTANCE
As recalled above, 50% of the patients treated with imatinib relapse
after 2 years (23). It is interesting to note that progression is some-
times marked by an increase in density, with or without an increase
in size. A sign of progression may also be the occurrence of an
area of CT-hyperdensity within a responding (hypodense) lesion.
This gives rise to the so-called “nodule within the nodule” pattern
(141). This underlines the need of a revision of the classical onco-
logic criteria for progression (145). Secondary mutations in KIT
or PDGFRA genes are the cause of most of the cases of secondary
resistance (23, 142, 146–148). They generally occur in the same
gene of the primary mutation. In KIT, they are localized in exon
13 or 17 of KIT, corresponding to the ATP-binding pocket and to
the activation loop, respectively, the most frequent being T607I in
the ATP-binding pocket (exon 13), followed by V654A (exon 13)
and T823D (exon 17) (60, 137, 149). In most cases, the secondary
mutation in PDGFRA is D842V. It is important to note that in
case of relapse constituted by multiple nodes, these are often mul-
ticlonal, with different mutations in different nodes (23, 60, 142,
150). This molecular heterogeneity can also explain the relatively
low efficacy of targeted therapy against relapsing GISTs.
OTHER MECHANISMS OF RESISTANCE
Amplification of KIT or PDGFRA gene has been implicated in
the development of resistance in RTK-wild-type GISTs (151).
Activation of alternate oncogenic pathways is another possible
Frontiers in Medicine | Pathology November 2014 | Volume 1 | Article 43 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
PI3K 
PDK1 
AKT 
Apoptosis 
JAK 
STAT1/3/5 
SRC 
RAC 
SHP2 
SHC 
GRB2 SOS 
RAS 
RAF 
MEK/ERK 
pp90srk 
JNK/SAP 
    Proliferation/   
Apoptosis 
JM 
RTK 
TK TK 
TK TK 
mTOR 
PTEN 
JM 
p16 
Imatinib 
Sunitinib 
Dasatinib 
Nilotinib 
Masatinib 
Vatalanib 
Regorafenib 
PKC 
PKC412 
Everolimus 
Sirolimus 
Regorafenib 
Sunitinib 
PKC412 
Vatalanib 
Perifosine 
(SF1126, XL147) 
 
ETV1 
FIGURE 3 | Possible therapeutic targets (red) and targeted drugs in GISTs.
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FIGURE 4 | Evolution of the concept of GISTs since 70 years. EM,
electron microscopy; IHC, immunohistochemistry; ICC, interstitial cells of
Cajal; MB, molecular biology; SDH, succinil dehydrogenase; IGFR, insuline
growth factor receptor; NGS, next generation sequencing.
resistance mechanism. This is the case of KRAS and BRAF (26)
or PI3K/AKT pathway upstream of mTOR (152). IGF1R may
represent another mechanism of resistance. It is expressed in
subsets of RTK wild-type GISTs (58, 153). IGF1R-targeted ther-
apy of wild-type GIST is being investigated in clinical trials
(e.g., NCT01560260) (154).
These possible alternate mechanisms of resistance (primary or
secondary) underline the necessity to develop schemes of therapy
with a broad mechanism of action. Besides inhibitors combina-
tion and inhibitors with a broad spectrum (sorafenib, masitinib,
vatalanib, nilotinib, or dasatinib that target also the VEGFR1 and
VEGFR2), an important possibility is, therefore, aiming at other
pathways. Promising targets are HSPs, histone deacetylases, signal-
ing intermediates, or pathways, such as mTOR, PI3K, or MAPK
[for review, see Ref. (138)].
CONCLUSION
The tremendous impact of molecular biology on modern medi-
cine cannot be overestimated. In my opinion, the most important
issue is the change of the paradigm of classification. GISTs repre-
sent a diagnostic category that changes its meaning and becomes
more complex in parallel to the development of diagnostic tools
and therapy (Figure 4). The non-committal term“GIST”probably,
covers different “entities” (e.g., pediatric GISTs or SDH-deficient
GISTs). A philosophical discussion on the actual meaning of the
word “entity” in pathology and medicine goes beyond the pur-
pose of this review. I think, however, that “entity” is an operative
concept, whose content depends and is modified on the basis of
the available diagnostic and therapeutic tools. This can be seen
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clearly in the case of GISTs. From the notion of a leiomyoma-
tous tumor, based on HE staining, we are now dealing with a
definition/classification that relies mainly on IHC stainings and
molecular techniques, whereas the latter are essential for defining
prognostic and therapeutic categories. The therapeutic strategy is
the most important criterium for a medical classification, since the
aim of medicine is the care of the patient. On the other hand, the
behavior of GISTs can be defined only by integrating the molecular
genetic findings with the “classical” clinicopathological parame-
ter. A modern disease classification must, therefore, rely on the
combination/integration of morphology and molecular biology
(Table 1).
REFERENCES
1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki
RG, et al. NCCN Task Force Report: update on the management of patients
with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 8(Suppl
2):S1–41.
2. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B,
et al. Gastrointestinal stromal tumors: the incidence,prevalence,clinical course,
and prognostication in the preimatinib mesylate era – a population-based study
in western Sweden. Cancer (2005) 103(4):821–9. doi:10.1002/cncr.20862
3. Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A,
et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are com-
mon in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007)
31(1):113–20. doi:10.1097/01.pas.0000213307.05811.f0
4. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are
common in incidental gastrointestinal stromal tumors one centimeter or less in
size.Am J Pathol (2002) 160(5):1567–72. doi:10.1016/S0002-9440(10)61103-0
5. Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, et al. High
incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum
Pathol (2006) 37(12):1527–35. doi:10.1016/j.humpath.2006.07.002
6. Muenst S, Thies S, Went P, Tornillo L, Bihl MP, Dirnhofer S. Frequency, pheno-
type, and genotype of minute gastrointestinal stromal tumors in the stomach:
an autopsy study. Hum Pathol (2011) 42(12):1849–54. doi:10.1016/j.humpath.
2011.01.024
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prog-
nosis at different sites. Semin Diagn Pathol (2006) 23(2):70–83. doi:10.1053/j.
semdp.2006.09.001
8. Stout AP. Tumors of the stomach. Bull N Y Acad Med (1947) 23(2):101–8.
9. Stout AP. Bizarre smooth muscle tumors of the stomach. Can-
cer (1962) 15:400–9. doi:10.1002/1097-0142(196203/04)15:2<400::AID-
CNCR2820150224>3.0.CO;2-P
10. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am
J Surg Pathol (1983) 7(6):507–19. doi:10.1097/00000478-198309000-00001
11. Miettinen M. Immunohistochemistry of soft tissue tumours – review with
emphasis on 10 markers. Histopathology (2014) 64(1):101–18. doi:10.1111/
his.12298
12. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD.
Gastrointestinal stromal tumors may originate from a subset of CD34-positive
interstitial cells of Cajal. Am J Pathol (2000) 156(4):1157–63. doi:10.1016/
S0002-9440(10)64984-X
13. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S,
et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal
tumors. Science (1998) 279(5350):577–80. doi:10.1126/science.279.5350.577
14. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M,
et al. A novel gain-of-function mutation of c-KIT gene in gastrointestinal
stromal tumors. Gastroenterology (1998) 115(5):1090–5. doi:10.1016/S0016-
5085(98)70079-4
15. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointesti-
nal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show
phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol (1998)
152(5):1259–69.
16. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sen-
sitive marker for gastrointestinal stromal tumors that is more specific than
CD34. Mod Pathol (1998) 11(8):728–34.
17. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A.
W/KIT gene required for interstitial cells of Cajal and for intestinal pacemaker
activity. Nature (1995) 373(6512):347–9. doi:10.1038/373347a0
18. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al.
Gain-of-function mutations of platelet-derived growth factor receptor alpha
gene in gastrointestinal stromal tumors.Gastroenterology (2003) 125(3):660–7.
doi:10.1016/S0016-5085(03)01046-1
19. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA
mutations in gastrointestinal stromal tumours. Histopathology (2008)
53(3):245–66. doi:10.1111/j.1365-2559.2008.02977.x
20. Agulnik M, Giel JL. Understanding rechallenge and resistance in the tyrosine
kinase inhibitor era: imatinib in gastrointestinal stromal tumor. Am J Clin
Oncol (2012) 37(4):417–22. doi:10.1097/COC.0b013e31824be3d6
21. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers.
J Pathol (2011) 223(2):251–61. doi:10.1002/path.2798
22. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P,
Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient
with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001)
344(14):1052–6. doi:10.1056/NEJM200104053441404
23. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al.
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs
through secondary gene mutation. Clin Cancer Res (2005) 11(11):4182–90.
doi:10.1158/1078-0432.CCR-04-2245
24. Tornillo L. Biology of GISTs and mechanisms of imatinib resistance. Diagn
Histopathol (2013) 19(6):203–10. doi:10.1016/j.mpdhp.2013.04.001
25. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A,
et al. V600E BRAF mutations are alternative early molecular events in a sub-
set of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol
(2009) 62(7):613–6. doi:10.1136/jcp.2009.064550
26. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A,
et al. KRAS and BRAF mutations predict primary resistance to imatinib
in gastrointestinal stromal tumors. Clin Cancer Res (2012) 18(6):1769–76.
doi:10.1158/1078-0432.CCR-11-2230
27. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage
survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Nature (2010) 467(7317):849–53. doi:10.1038/nature09409
28. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved
features and deduced phylogeny of the catalytic domains. Science (1988)
241(4861):42–52. doi:10.1126/science.3291115
29. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: ori-
gin and molecular oncology. Nat Rev Cancer (2011) 11(12):865–78. doi:10.
1038/nrc3143
30. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S,
et al. Mechanisms of oncogenic KIT signal transduction in primary gas-
trointestinal stromal tumors (GISTs). Oncogene (2004) 23(22):3999–4006.
doi:10.1038/sj.onc.1207525
31. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N,
et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science
(2003) 299(5607):708–10. doi:10.1126/science.1079666
32. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, et al. Correlation of KIT
and platelet-derived growth factor receptor alpha mutations with gene acti-
vation and expression profiles in gastrointestinal stromal tumors. Oncogene
(2005) 24(6):1066–74. doi:10.1038/sj.onc.1208358
33. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, et al. Oncogenic
KIT signaling and therapeutic intervention in a mouse model of gastroin-
testinal stromal tumor. Proc Natl Acad Sci U S A (2006) 103(34):12843–8.
doi:10.1073/pnas.0511076103
34. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation
is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res (2001)
61(22):8118–21.
35. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, et al.
In utero manipulation of coat color formation by a monoclonal anti-c-KIT
antibody: two distinct waves of c-KIT-dependency during melanocyte devel-
opment. EMBO J (1991) 10(8):2111–8.
36. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct
subtypes of melanoma. J Clin Oncol (2006) 24(26):4340–6. doi:10.1200/JCO.
2006.06.2984
37. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, et al. c-KIT
proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute
Frontiers in Medicine | Pathology November 2014 | Volume 1 | Article 43 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
myeloid leukaemia. Br J Haematol (1999) 105(4):894–900. doi:10.1046/j.1365-
2141.1999.01449.x
38. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y,
et al. Identification of a point mutation in the catalytic domain of the pro-
tooncogene c-KIT in peripheral blood mononuclear cells of patients who have
mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S
A (1995) 92(23):10560–4. doi:10.1073/pnas.92.23.10560
39. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-KIT gene
mutations in human germ cell tumors. Am J Pathol (1999) 154(6):1643–7.
doi:10.1016/S0002-9440(10)65419-3
40. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, et al.
Structural basis for the autoinhibition and STI-571 inhibition of c-KIT tyrosine
kinase. J Biol Chem (2004) 279(30):31655–63. doi:10.1074/jbc.M403319200
41. Antonescu C. Gastrointestinal stromal tumors. Curr Top Microbiol Immunol
(2012) 355:41–57. doi:10.1007/82_2011_161
42. Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joen-
suu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions
are associated with poor prognosis. Gastroenterology (2006) 130(6):1573–81.
doi:10.1053/j.gastro.2006.01.043
43. Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA, Garcia
del Muro J, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate
a poor prognosis in patients with completely resected gastrointestinal stromal
tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin
Oncol (2005) 23(25):6190–8. doi:10.1200/JCO.2005.19.554
44. Tzen CY, Mau BL. Analysis of CD117-negative gastrointestinal stromal tumors.
World J Gastroenterol (2005) 11(7):1052–5.
45. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et al. Deletion of
Trp-557 and Lys-558 in the juxtamembrane domain of the c-KIT protoonco-
gene is associated with metastatic behavior of gastrointestinal stromal tumors.
Int J Cancer (2003) 106(6):887–95. doi:10.1002/ijc.11323
46. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff
JM, et al. Association of KIT exon 9 mutations with nongastric primary site
and aggressive behavior: KIT mutation analysis and clinical correlates of 120
gastrointestinal stromal tumors. Clin Cancer Res (2003) 9(9):3329–37.
47. Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki
M, Steigen SE, et al. Gastrointestinal stromal tumors with internal tandem
duplications in 3’ end of KIT juxtamembrane domain occur predominantly
in stomach and generally seem to have a favorable course. Mod Pathol (2003)
16(12):1257–64. doi:10.1097/01.MP.0000097365.72526.3E
48. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointesti-
nal stromal tumours. J Clin Pathol (2006) 59(6):557–63. doi:10.1136/jcp.2005.
031112
49. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, et al. KIT extra-
cellular and kinase domain mutations in gastrointestinal stromal tumors. Am
J Pathol (2000) 156(3):791–5. doi:10.1016/S0002-9440(10)64946-2
50. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH,
et al. Gene expression in gastrointestinal stromal tumors is distinguished by
KIT genotype and anatomic site. Clin Cancer Res (2004) 10(10):3282–90.
doi:10.1158/1078-0432.CCR-03-0715
51. Battochio A, Mohammed S, Winthrop D, Lefresne S, Mulder K, Chu Q, et al.
Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal
tumors: comparison of DHPLC and DNA sequencing methods using a single
population-based cohort. Am J Clin Pathol (2010) 133(1):149–55.
52. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E,
et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with
primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.
Mod Pathol (2008) 21(4):476–84. doi:10.1038/modpathol.2008.2
53. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors
of the jejunum and ileum: a clinicopathologic, immunohistochemical, and
molecular genetic study of 906 cases before imatinib with long-term follow-
up. Am J Surg Pathol (2006) 30(4):477–89. doi:10.1097/00000478-200604000-
00008
54. Cho S, Kitadai Y, Yoshida S, Tanaka S, Yoshihara M, Yoshida K, et al. Dele-
tion of the KIT gene is associated with liver metastasis and poor prognosis in
patients with gastrointestinal stromal tumor in the stomach. Int J Oncol (2006)
28(6):1361–7. doi:10.3892/ijo.28.6.1361
55. Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M, et al. c-KIT
gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal
tumors. J GastroenterolHepatol (2003) 18(2):147–51. doi:10.1046/j.1440-1746.
2003.02911.x
56. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M. Mutations in gastroin-
testinal stromal tumors – a population-based study from Northern Norway.
APMIS (2007) 115(4):289–98. doi:10.1111/j.1600-0463.2007.apm_587.x
57. Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer HP, et al.
c-KIT mutations in gastrointestinal stromal tumors occur preferentially in
the spindle rather than in the epithelioid cell variant. Mod Pathol (2002)
15(2):125–36. doi:10.1038/modpathol.3880504
58. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, et al. Molec-
ular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer
Res (2008) 14(10):3204–15. doi:10.1158/1078-0432.CCR-07-1984
59. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P,
van Oosterom AT, et al. KIT mutations and dose selection for imatinib in
patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006)
42(8):1093–103. doi:10.1016/j.ejca.2006.01.030
60. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Hetero-
geneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008)
216(1):64–74. doi:10.1002/path.2382
61. Huss S, Kunstlinger H, Wardelmann E, Kleine MA, Binot E, Merkelbach-Bruse
S, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-
type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).
Mod Pathol (2013) 26(7):1004–12. doi:10.1038/modpathol.2013.47
62. Daniels M, Lurkin I, Pauli R, Erbstosser E, Hildebrandt U, Hellwig K, et al. Spec-
trum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase
pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer
Lett (2011) 312(1):43–54. doi:10.1016/j.canlet.2011.07.029
63. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, et al.
Protein kinase C theta (PKCtheta) expression and constitutive activation in
gastrointestinal stromal tumors (GISTs). Cancer Res (2004) 64(15):5127–31.
doi:10.1158/0008-5472.CAN-04-0559
64. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV, Alkan S. Analysis
of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal
stromal tumors. Anticancer Res (2003) 23(3B):2253–60.
65. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR,
et al. A knock-in mouse model of gastrointestinal stromal tumor harboring
KIT K641E. Cancer Res (2005) 65(15):6631–9. doi:10.1158/0008-5472.CAN-
05-0891
66. Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA. KIT onco-
protein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Oncogene (2007) 26(44):6386–95. doi:10.1038/sj.onc.1210464
67. Kuzu G, Keskin O, Gursoy A, Nussinov R. Constructing structural networks
of signaling pathways on the proteome scale. Curr Opin Struct Biol (2012)
22(3):367–77. doi:10.1016/j.sbi.2012.04.004
68. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N.
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in
cancer pathogenesis and implications for therapeutic approaches. Expert
Opin Ther Targets (2012) 16(Suppl 2):S17–27. doi:10.1517/14728222.2011.
639361
69. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges.
Mol Interv (2011) 11(1):18–26. doi:10.1124/mi.11.1.4
70. Birner P, Beer A, Vinatzer U, Stary S, Hoftberger R, Nirtl N, et al. MAPKAP
kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors
and associates with copy number variations on chromosome 1 and expres-
sion of p38 MAP kinase and ETV1. Clin Cancer Res (2012) 18(7):1879–87.
doi:10.1158/1078-0432.CCR-11-2364
71. Zhang Y, Gu ML, Zhou XX, Ma H, Yao HP, Ji F. Altered expression of ETV1 and
its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors.
Oncol Rep (2014) 32(3):927–34. doi:10.3892/or.2014.3281
72. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibi-
tion in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006)
66(18):9153–61. doi:10.1158/0008-5472.CAN-06-0165
73. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-
demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated,
constitutively activated KIT protein in human mast cells. Blood (2004)
103(3):1078–84. doi:10.1182/blood-2003-07-2477
74. Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M,
et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive
www.frontiersin.org November 2014 | Volume 1 | Article 43 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther (2012)
11(8):1799–808. doi:10.1158/1535-7163.MCT-11-1046
75. Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. PDGFRalpha-
and c-KIT-mutated gastrointestinal stromal tumours (GISTs) are characterized
by distinctive histological and immunohistochemical features. Histopathology
(2005) 46(2):166–75. doi:10.1111/j.1365-2559.2005.02061.x
76. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J.
Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarco-
mas in the rectum and anus: a clinicopathologic, immunohistochemical, and
molecular genetic study of 144 cases. Am J Surg Pathol (2001) 25(9):1121–33.
doi:10.1097/00000478-200111000-00013
77. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H,
Burke A, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and
leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochem-
ical, and molecular genetic study of 167 cases. Am J Surg Pathol (2003)
27(5):625–41. doi:10.1097/00000478-200305000-00006
78. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal
tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohis-
tochemical, and molecular genetic study of 44 cases. Am J Surg Pathol (2000)
24(10):1339–52. doi:10.1097/00000478-200010000-00003
79. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G.
The location of KIT and PDGFRA gene mutations in gastrointestinal stromal
tumours is site and phenotype associated. J Clin Pathol (2005) 58(6):634–9.
doi:10.1136/jcp.2004.021766
80. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority
of GISTs with PDGFRA mutations represent gastric tumors of low or no malig-
nant potential. Lab Invest (2004) 84(7):874–83. doi:10.1038/labinvest.3700122
81. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations
represent subset of clinically favorable gastric tumors with epithelioid mor-
phology. Lab Invest (2006) 86(1):94–100. doi:10.1038/labinvest.3700360
82. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohen-
berger P, et al. Association of platelet-derived growth factor receptor alpha
mutations with gastric primary site and epithelioid or mixed cell morphol-
ogy in gastrointestinal stromal tumors. J Mol Diagn (2004) 6(3):197–204.
doi:10.1016/S1525-1578(10)60510-7
83. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, et al.
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA muta-
tions have distinct gene expression profiles. Oncogene (2004) 23(47):7780–90.
doi:10.1038/sj.onc.1208056
84. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer
A, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117
antigen) immunoreactivity. J Pathol (2004) 202(4):430–8. doi:10.1002/path.
1546
85. Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-
derived growth factor receptor alpha is destabilized by geldanamycins in cancer
cells. J Biol Chem (2007) 282(1):445–53. doi:10.1074/jbc.M607012200
86. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of
gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol (2009)
33(9):1401–8. doi:10.1097/PAS.0b013e3181a90e1a
87. Wozniak A, Sciot R, Guillou L, Pauwels P, Wasag B, Stul M, et al. Array CGH
analysis in primary gastrointestinal stromal tumors: cytogenetic profile cor-
relates with anatomic site and tumor aggressiveness, irrespective of muta-
tional status. Genes Chromosomes Cancer (2007) 46(3):261–76. doi:10.1002/
gcc.20408
88. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al.
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum
and in vitro sensitivity to imatinib. J Clin Oncol (2005) 23(23):5357–64.
doi:10.1200/JCO.2005.14.068
89. Daum O, Grossmann P, Vanecek T, Sima R, Mukensnabl P, Michal M. Diag-
nostic morphological features of PDGFRA-mutated gastrointestinal stro-
mal tumors: molecular genetic and histologic analysis of 60 cases of gas-
tric gastrointestinal stromal tumors. Ann Diagn Pathol (2007) 11(1):27–33.
doi:10.1016/j.anndiagpath.2006.10.002
90. Haller F, Happel N, Schulten HJ, von Heydebreck A, Schwager S, Armbrust T,
et al. Site-dependent differential KIT and PDGFRA expression in gastric and
intestinal gastrointestinal stromal tumors. Mod Pathol (2007) 20(10):1103–11.
doi:10.1038/modpathol.3800947
91. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joen-
suu H, et al. Kinase mutations and imatinib response in patients with
metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 21(23):4342–9.
doi:10.1200/JCO.2003.04.190
92. Holden JA, Willmore-Payne C, Coppola D, Garrett CR, Layfield LJ. High-
resolution melting amplicon analysis as a method to detect c-KIT and platelet-
derived growth factor receptor alpha activating mutations in gastrointesti-
nal stromal tumors. Am J Clin Pathol (2007) 128(2):230–8. doi:10.1309/
7TEH56K6WWXENNQY
93. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC,
et al. KIT-negative gastrointestinal stromal tumors: proof of concept and ther-
apeutic implications. Am J Surg Pathol (2004) 28(7):889–94. doi:10.1097/
00000478-200407000-00007
94. Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T, et al.
Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infil-
trations: a subtype of GIST with mutations of platelet-derived growth fac-
tor receptor alpha gene. Hum Pathol (2004) 35(10):1223–30. doi:10.1016/j.
humpath.2004.07.008
95. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV,
et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid
and mixed variants of gastrointestinal stromal tumors depends predominantly
on the tumor site. Mod Pathol (2004) 17(8):889–94. doi:10.1038/modpathol.
3800136
96. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF
mutation status in gastrointestinal stromal tumors. Am J Clin Pathol (2010)
133(1):141–8. doi:10.1309/AJCPPCKGA2QGBJ1R
97. Lasota J, Xi L, Coates T, Dennis R, Evbuomwan MO, Wang ZF, et al. No
KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular
genetic study of 514 cases. Mod Pathol (2013) 26(11):1488–91. doi:10.1038/
modpathol.2013.89
98. Ward BA, Gutmann DH. Neurofibromatosis 1: from lab bench to clinic. Pediatr
Neurol (2005) 32(4):221–8. doi:10.1016/j.pediatrneurol.2004.11.002
99. Nannini M, Biasco G, Astolfi A, Pantaleo MA. An overview on molecular biol-
ogy of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
J Med Genet (2013) 50(10):653–61. doi:10.1136/jmedgenet-2013-101695
100. Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y, et al. Absence
of c-KIT gene mutations in gastrointestinal stromal tumours from neurofibro-
matosis type 1 patients. J Pathol (2004) 202(1):80–5. doi:10.1002/path.1487
101. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in
patients with neurofibromatosis 1: a clinicopathologic and molecular genetic
study of 45 cases. Am J Surg Pathol (2006) 30(1):90–6. doi:10.1097/01.pas.
0000176433.81079.bd
102. Nemoto H, Tate G, Schirinzi A, Suzuki T, Sasaya S, Yoshizawa Y, et al. Novel
NF1 gene mutation in a Japanese patient with neurofibromatosis type 1
and a gastrointestinal stromal tumor. J Gastroenterol (2006) 41(4):378–82.
doi:10.1007/s00535-006-1772-7
103. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, et al.
Gastrointestinal stromal tumors of neurofibromatosis type I (von Reckling-
hausen’s disease). Am J Surg Pathol (2005) 29(6):755–63. doi:10.1097/01.pas.
0000163359.32734.f9
104. Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR. Multiple gas-
trointestinal stromal tumors in type I neurofibromatosis: a pathologic and
molecular study. Mod Pathol (2005) 18(4):475–84. doi:10.1038/modpathol.
3800334
105. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, et al.
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1
patients. HumMol Genet (2006) 15(6):1015–23. doi:10.1093/hmg/ddl016
106. Rutter J, Winge DR, Schiffman JD. Succinate dehydrogenase – assembly, reg-
ulation and role in human disease. Mitochondrion (2010) 10(4):393–401.
doi:10.1016/j.mito.2010.03.001
107. Barletta JA, Hornick JL. Succinate dehydrogenase-deficient tumors: diagnos-
tic advances and clinical implications. Adv Anat Pathol (2012) 19(4):193–203.
doi:10.1097/PAP.0b013e31825c6bc6
108. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia.
Pathology (2012) 44(4):285–92. doi:10.1097/PAT.0b013e3283539932
109. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects
in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT
Frontiers in Medicine | Pathology November 2014 | Volume 1 | Article 43 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
and PDGFRA mutations. Proc Natl Acad Sci U S A (2011) 108(1):314–8.
doi:10.1073/pnas.1009199108
110. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota
J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohis-
tochemical, and molecular genetic study of 66 gastric GISTs with predilec-
tion to young age. Am J Surg Pathol (2011) 35(11):1712–21. doi:10.1097/PAS.
0b013e3182260752
111. Chou A, Chen J, Clarkson A, Samra JS, Clifton-Bligh RJ, Hugh TJ, et al. Suc-
cinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpres-
sion. Mod Pathol (2012) 25(9):1307–13. doi:10.1038/modpathol.2012.77
112. Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL. Loss of succi-
nate dehydrogenase subunit B (SDHB) expression is limited to a distinctive
subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive
genotype-phenotype correlation study. Histopathology (2012) 61(5):801–9.
doi:10.1111/j.1365-2559.2012.04300.x
113. Gaal J, Stratakis CA, Carney JA, Ball ER, Korpershoek E, Lodish MB, et al. SDHB
immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and
Carney triad gastrointestinal stromal tumors.ModPathol (2011) 24(1):147–51.
doi:10.1038/modpathol.2010.185
114. Gill AJ,Chou A,Vilain R,Clarkson A,Lui M,Jin R,et al. Immunohistochemistry
for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.
Am J Surg Pathol (2010) 34(5):636–44. doi:10.1097/PAS.0b013e3181d6150d
115. Gill AJ, Chou A, Vilain RE, Clifton-Bligh RJ. “Pediatric-type” gastrointestinal
stromal tumors are SDHB negative (“type 2”) GISTs. Am J Surg Pathol (2011)
35(8):1245–7; author reply 7–8. doi:10.1097/PAS.0b013e3182217b93
116. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. “Pediatric-
type” gastrointestinal stromal tumors in adults: distinctive histology pre-
dicts genotype and clinical behavior. Am J Surg Pathol (2011) 35(4):495–504.
doi:10.1097/PAS.0b013e31820e5f7d
117. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma:
a new syndrome distinct from the Carney triad. Am J Med Genet (2002)
108(2):132–9. doi:10.1002/ajmg.10235
118. Italiano A, Chen CL, Sung YS, Singer S, DeMatteo RP, LaQuaglia MP, et al.
SDHA loss of function mutations in a subset of young adult wild-type gas-
trointestinal stromal tumors. BMC Cancer (2012) 12:408. doi:10.1186/1471-
2407-12-408
119. Wardelmann E. Translational research and diagnosis in GIST. Pathologe (2012)
33(Suppl 2):273–7. doi:10.1007/s00292-012-1682-9
120. Miettinen M, Lasota J. Succinate dehydrogenase deficient gastrointestinal stro-
mal tumors (GISTs) – A review. Int J Biochem Cell Biol (2014) 53:514–9.
doi:10.1016/j.biocel.2014.05.033
121. Briere JJ, Favier J, Benit P, El Ghouzzi V, Lorenzato A, Rabier D, et al. Mito-
chondrial succinate is instrumental for HIF1alpha nuclear translocation in
SDHA-mutant fibroblasts under normoxic conditions. HumMol Genet (2005)
14(21):3263–9. doi:10.1093/hmg/ddi359
122. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield
KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting
HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 7(1):77–85. doi:10.1016/j.
ccr.2004.11.022
123. Lasota J, Wang Z, Kim SY, Helman L, Miettinen M. Expression of the
receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal
stromal tumors: an immunohistochemical study of 1078 cases with diag-
nostic and therapeutic implications. Am J Surg Pathol (2013) 37(1):114–9.
doi:10.1097/PAS.0b013e3182613c86
124. Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL, et al.
Gene expression of the IGF pathway family distinguishes subsets of gastroin-
testinal stromal tumors wild type for KIT and PDGFRA. Cancer Med (2013)
2(1):21–31. doi:10.1002/cam4.57
125. Rikhof B, van der Graaf WT, Suurmeijer AJ, van Doorn J, Meersma GJ, Groenen
PJ, et al. “Big”-insulin-like growth factor-II signaling is an autocrine survival
pathway in gastrointestinal stromal tumors.Am J Pathol (2012) 181(1):303–12.
doi:10.1016/j.ajpath.2012.03.028
126. Breiner JA, Meis-Kindblom J, Kindblom LG, McComb E, Liu J, Nelson M,
et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell
tumors). Cancer Genet Cytogenet (2000) 120(2):111–6. doi:10.1016/S0165-
4608(00)00212-0
127. Derre J, Lagace R, Terrier P, Sastre X, Aurias A. Consistent DNA losses on
the short arm of chromosome 1 in a series of malignant gastrointestinal
stromal tumors. Cancer Genet Cytogenet (2001) 127(1):30–3. doi:10.1016/
S0165-4608(00)00409-X
128. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA
sequence copy number changes in gastrointestinal stromal tumors: tumor pro-
gression and prognostic significance. Cancer Res (2000) 60(14):3899–903.
129. Gunawan B, von Heydebreck A, Sander B, Schulten HJ, Haller F, Langer C, et al.
An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) iden-
tifies different pathways of cytogenetic evolution with prognostic implications.
J Pathol (2007) 211(4):463–70. doi:10.1002/path.2128
130. Ylipaa A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, et al. Integrative
genomic characterization and a genomic staging system for gastrointestinal
stromal tumors. Cancer (2011) 117(2):380–9. doi:10.1002/cncr.25594
131. Tornillo L, Duchini G, Carafa V, Lugli A, Dirnhofer S, Di Vizio D, et al. Patterns
of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest
(2005) 85(7):921–31. doi:10.1038/labinvest.3700284
132. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V,
et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors char-
acterized for c-KIT and platelet-derived growth factor receptor alpha gene
alterations. Cancer (2005) 104(1):159–69. doi:10.1002/cncr.21113
133. Schneider-Stock R,Boltze C,Lasota J,Miettinen M,Peters B,Pross M,et al. High
prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J
Clin Oncol (2003) 21(9):1688–97. doi:10.1200/JCO.2003.08.101
134. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al.
Loss of p16 protein defines high-risk patients with gastrointestinal stromal
tumors: a tissue microarray study. Clin Cancer Res (2005) 11(2 Pt 1):638–45.
135. Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S,
et al. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-
dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J
Pathol (2008) 215(3):253–62. doi:10.1002/path.2352
136. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of
gastrointestinal stromal tumors: before and after STI-571. Hum Pathol (2002)
33(5):466–77. doi:10.1053/hupa.2002.124122
137. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al.
Primary and secondary kinase genotypes correlate with the biological and clin-
ical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J
Clin Oncol (2008) 26(33):5352–9. doi:10.1200/JCO.2007.15.7461
138. Montemurro M, Bauer S. Treatment of gastrointestinal stromal tumor after
imatinib and sunitinib. Curr Opin Oncol (2011) 23(4):367–72. doi:10.1097/
CCO.0b013e3283477ac2
139. Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D, et al.
Autophagy inhibition and antimalarials promote cell death in gastrointesti-
nal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 107(32):14333–8.
doi:10.1073/pnas.1000248107
140. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Dis-
continuation of imatinib in patients with advanced gastrointestinal stromal
tumours after 3 years of treatment: an open-label multicentre randomised
phase 3 trial. Lancet Oncol (2010) 11(10):942–9. doi:10.1016/S1470-2045(10)
70222-9
141. Casali PG. Successes and limitations of targeted cancer therapy in gastrointesti-
nal stromal tumors. Prog Tumor Res (2014) 41:51–61. doi:10.1159/000355898
142. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al.
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
J Clin Oncol (2006) 24(29):4764–74. doi:10.1200/JCO.2006.06.2265
143. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine
kinase inhibitor resistance in gastrointestinal stromal tumor.Cancer Chemother
Pharmacol (2011) 67(Suppl 1):S25–43. doi:10.1007/s00280-010-1526-3
144. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects
of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants
with differential imatinib sensitivity. Gastroenterology (2006) 131(6):1734–42.
doi:10.1053/j.gastro.2006.09.017
145. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR,
et al. Correlation of computed tomography and positron emission tomogra-
phy in patients with metastatic gastrointestinal stromal tumor treated at a sin-
gle institution with imatinib mesylate: proposal of new computed tomography
response criteria. J Clin Oncol (2007) 25(13):1753–9. doi:10.1200/JCO.2006.
07.3049
146. Grimpen F,Yip D, McArthur G,Waring P, Goldstein D, Loughrey M, et al. Resis-
tance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17
www.frontiersin.org November 2014 | Volume 1 | Article 43 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tornillo An evolving concept
mutation in gastrointestinal stromal tumour. Lancet Oncol (2005) 6(9):724–7.
doi:10.1016/S1470-2045(05)70321-1
147. Koyama T, Nimura H, Kobayashi K, Marushima H, Odaira H, Kashimura H,
et al. Recurrent gastrointestinal stromal tumor (GIST) of the stomach asso-
ciated with a novel c-KIT mutation after imatinib treatment. Gastric Cancer
(2006) 9(3):235–9. doi:10.1007/s10120-006-0368-5
148. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. Late resis-
tance to imatinib therapy in a metastatic gastrointestinal stromal tumour
is associated with a second KIT mutation. Br J Cancer (2004) 90(11):
2059–61. doi:10.1038/sj.bjc.6601819
149. Roskoski R Jr. Structure and regulation of KIT protein-tyrosine kinase – the
stem cell factor receptor.BiochemBiophysResCommun (2005) 338(3):1307–15.
doi:10.1016/j.bbrc.2005.09.150
150. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, et al.
Clonal evolution of resistance to imatinib in patients with metastatic gas-
trointestinal stromal tumors. Clin Cancer Res (2007) 13(18 Pt 1):5398–405.
doi:10.1158/1078-0432.CCR-06-0858
151. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, et al.
c-KIT/PDGFRA gene status alterations possibly related to primary ima-
tinib resistance in gastrointestinal stromal tumors. Clin Cancer Res (2007)
13(8):2369–77. doi:10.1158/1078-0432.CCR-06-1745
152. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signal-
ing mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-
kinase/AKT is a crucial survival pathway. Oncogene (2007) 26(54):7560–8.
doi:10.1038/sj.onc.1210558
153. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-
like growth factor 1 receptor is a potential therapeutic target for gastroin-
testinal stromal tumors. Proc Natl Acad Sci U S A (2008) 105(24):8387–92.
doi:10.1073/pnas.0803383105
154. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE,
et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal
antibody to IGF-1R in combination with multiple standard oncology regimens
in patients with advanced solid malignancies. Cancer Chemother Pharmacol
(2014) 73(3):467–73. doi:10.1007/s00280-013-2372-x
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 19 August 2014; accepted: 17 October 2014; published online: 11 November
2014.
Citation: Tornillo L (2014) Gastrointestinal stromal tumor – an evolving concept.
Front. Med. 1:43. doi: 10.3389/fmed.2014.00043
This article was submitted to Pathology, a section of the journal Frontiers in Medicine.
Copyright © 2014 Tornillo. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Medicine | Pathology November 2014 | Volume 1 | Article 43 | 12
